Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Cyclacel Pharmaceuticals Inc    

CYCLACEL PHARMACEUTICALS INC
Mes dernières consult.
Most popular
  Report  
 SummaryNewsCalendarCompanyFinancialsConsensus 
Company
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company.It uses cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases.The company builds a diversified biopharmaceutical... 
More about the company
Latest news on CYCLACEL PHARMACEUTICALS I
11:17aCYCLACEL PHARMACEUTICALS : Announces Presentation of Phase 1 Clinical Data for C..
AQ
04/17Cyclacel’s CYC065 CDK Inhibitor Demonstrates Synergy With Venetoclax By..
GL
04/17CYCLACEL PHARMACEUTICALS : Announces Presentation of Phase 1 Clinical Data for C..
AQ
04/16Cyclacel Announces Presentation of Phase 1 Clinical Data for CDK Inhibitor CY..
GL
04/02CYCLACEL PHARMACEUTICALS : Reports Fourth Quarter and Full Year 2017 Financial R..
AQ
03/28CYCLACEL PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, ..
AQ
03/28Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial ..
GL
03/28CYCLACEL PHARMACEUTICALS INC : Cyclacel Pharmaceuticals, Inc. to Host Earnings C..
AC
03/26CYCLACEL PHARMACEUTICALS : to Release Fourth Quarter and Full Year 2017 Financia..
AQ
03/22CYCLACEL PHARMACEUTICALS : to Release Fourth Quarter and Full Year 2017 Financia..
AQ
More news
Sector news : Bio Therapeutic Drugs
02:09pNovartis CEO feels heat on U.S. generics, Cosentyx drop
RE
04/17GE rides gene therapy wave with ready-made viral drug factories
RE
04/12GSK slims portfolio with sale of rare disease gene therapy drugs
RE
04/12UK gene therapy firm Orchard plans stock offer after GSK deal
RE
04/12TAKEDA SOUNDS OUT BANKS FOR LOANS AS : sources
RE
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
2016Midday Gainers / Losers 
2016Midday Gainers / Losers 
2016Cyclacel's lead product candidates show encouraging results in early-stage st.. 
2016HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am 
2016Some Ideas For The Next Celator 
Chart CYCLACEL PHARMACEUTICALS I
Duration : Period :
Cyclacel Pharmaceuticals I Technical Analysis Chart | US23254L3069 | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 7,00 $
Spread / Average Target 379%
Managers
NameTitle
Spiro Rombotis President, Chief Executive Officer & Director
David C. U'Prichard Chairman
Paul McBarron COO, CFO, Secretary, Director & Executive VP
David Glover Chief Scientist
John Michael Middlecott Banham Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CYCLACEL PHARMACEUTICALS INC18
GILEAD SCIENCES5.35%98 675
VERTEX PHARMACEUTICALS10.10%41 476
REGENERON PHARMACEUTICALS-14.19%34 613
GENMAB15.65%12 876
BEIGENE LTD (ADR)73.08%9 059